title: Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers.
abstract: The excretion, biotransformation, and pharmacokinetics of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, were investigated in six healthy male volunteers, phenotyped either as CYP2D6 extensive or poor metabolizers of dextromethorphan. Each subject received an i.v. infusion of a single 50-mg (100 microCi) dose of [(14)C]traxoprodil. Approximately 89% of the administered dose was recovered in poor metabolizers (PMs) and 61% in extensive metabolizers (EMs), with the majority of the dose being excreted in the urine (86% in PMs and 52% in EMs). The elimination of traxoprodil was more rapid in EMs than in PMs with terminal elimination half-lives of 2.8 and 26.9 h, respectively, for EMs and PMs. Area under the plasma concentration-time curve from time 0 to T (AUC((0-Tlast))) values for unchanged traxoprodil were 1.2 and 32.7% of the corresponding AUC values for total radioactivity in EMs and PMs, respectively. Traxoprodil was metabolized in both EMs and PMs, with approximately 7 and 50% of the administered radioactivity excreted as unchanged drug in the excreta of EMs and PMs, respectively. Hydroxylation at the 3-position of the hydroxyphenyl ring and methylation of the resulting catechol followed by conjugation were identified as the main metabolic pathways in EMs. In contrast, direct conjugation of traxoprodil with glucuronic or sulfuric acid was the major pathway in PMs. In vitro studies using CYP2D6-selective inhibitor and recombinant enzyme also support that the metabolism of traxoprodil is mainly mediated by CYP2D6. Taken together, these studies suggest that traxoprodil is eliminated mainly by Phase I oxidative metabolism mediated by CYP2D6 isozyme in EMs and by Phase II conjugation and renal clearance of parent in PMs.
authors.affiliation: Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Groton, Connecticut 06340, USA.
authors.forename: Kim
authors.initials: K
authors.lastname: Johnson
authors.forename: Ajit
authors.initials: A
authors.lastname: Shah
authors.forename: Sarah
authors.initials: S
authors.lastname: Jaw-Tsai
authors.forename: James
authors.initials: J
authors.lastname: Baxter
authors.forename: Chandra
authors.initials: C
authors.lastname: Prakash
mesh_terms: D000293:Adolescent; D000328:Adult; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism*; D018691:Excitatory Amino Acid Antagonists / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine*; D006801:Humans; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D008875:Middle Aged; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D019389:Cytochrome P-450 CYP2D6